Sign inJoin waitlistJoin the waitlist

Filipa Lynce

Director, Inflammatory Breast Center · Mass General Brigham

Credentials: · · · ·

History

Inflammatory Breast Center · Mass General Brigham
Present
Mass General Brigham
Present

MedStar Washington Hospital Center
2007–2009
MedStar Washington Hospital Center
2004–2007
Universidade Nova de Lisboa Faculdade de Ciências Médicas
2000–2004

Research

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
New England Journal of Medicine · 2021 · 1,378 citations
Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types
JCO Precision Oncology · 2018 · 396 citations
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
JAMA Oncology · 2019 · 378 citations

Sara Tolaney
30 papers
Claudine Isaacs
28 papers
Faina Nakhlis
17 papers
BO
Beth Overmoyer
16 papers
Paula Pohlmann
16 papers
SS
Sandra Swain
16 papers
JB
Jennifer Bellon
14 papers
Nancy Lin
12 papers
BH
Beth Harrison
10 papers
CG
Christopher Gallagher
10 papers
Ana Garrido-Castro
9 papers · 3 as a fellow
Ann Partridge
9 papers

Grants

Macrophage-Directed Strategies for BRCA-Associated Breast Cancer
National Cancer Institute · R01
PI · $772.2K · Brigham and Women's Hospital
2026–2031

Clinical trials

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Principal investigator · Recruiting · Phase 1
National Cancer Institute (NCI)
2026–2028
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
Principal investigator · Recruiting · Phase 1
Dana-Farber Cancer Institute
2024–2029
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
Principal investigator · Terminated · Phase 1
Filipa Lynce, MD
2024–2026
TRUDI: TDXD+Durva in HER2+/Low IBC
Principal investigator · Recruiting · Phase 2
Filipa Lynce, MD
2023–2032